• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Strados Labs and BIDMC Launch Study to Evaluate AI-Powered Biosensor for Early Detection of Pulmonary Edema

by Jasmine Pennic 02/21/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

   

What You Should Know: 

– Strados Labs, a medical technology company focused on respiratory health, today announced a new collaboration with Beth Israel Deaconess Medical Center (BIDMC) to evaluate the use of its RESP® Biosensor for the early detection of pulmonary edema in critically ill patients.

– The pilot study, scheduled to begin at the end of February 2025, will enroll 20 patients and is expected to last 12 months.

Study Design and Objectives

Pulmonary edema, a condition where fluid accumulates in the lungs, is a common and life-threatening complication for patients on mechanical ventilation (MV). Early detection is crucial for effective intervention and improved outcomes. This study will investigate whether the RESP Biosensor, a wearable stethoscope technology, can detect subtle changes in lung sounds that precede traditional markers of pulmonary edema.

This single-center, prospective, observational study will compare the performance of the RESP Biosensor to existing monitoring methods, such as daily chest X-rays, clinical assessments, and fluid intake/output tracking. The primary objective is to determine if the biosensor can identify early signs of pulmonary edema before they are detectable through conventional methods.

RESP Biosensor: A Breakthrough in Continuous Lung Monitoring

The RESP Biosensor is an FDA-cleared and CE-marked wearable device that continuously captures lung sounds, including cough, wheeze, and crackles. This technology has been used in various patient populations and disease states, such as chronic cough, COPD, asthma, and heart failure. This study marks the first time the RESP Biosensor will be used to monitor patients on MV for pulmonary edema.

Expanding Applications for Lung Sound Monitoring

This study is part of a broader effort to evaluate the potential of the RESP Biosensor to improve patient care across various respiratory conditions. The findings are expected to guide future research and expand the applications of continuous lung sound monitoring.

“Pulmonary edema presents significant challenges in the ICU, with delayed detection often leading to poorer outcomes for patients,” said Nick Delmonico, CEO & Cofounder at Strados Labs. “We’re excited to collaborate with the esteemed team at BIDMC to explore whether continuous monitoring of lung sounds could lead to earlier and prompt interventions in pulmonary edema.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Biosensors

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |